UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ Commission File Number: 001-38067 (Exact name of Registrant as specified in its Charter) United Kingdom 98-1489389 (State or other jurisdiction of in ...

Verona Pharma plc (NASDAQ:VRNA) Q3 2020 Earnings Conference Call October 29, 2020 9:00 PM ET Company Participants David Zaccardelli - CEO Mark Hahn - CFO Kathy Rickard - CMO Chris Martin - VP, Commercial Conference Call Participants Joon Lee - Truist Securities Suji Jeong - Jefferies Tom Shrader - BTIG Edward Nash - Canaccord Genuity Operator Welcome to the Verona Pharma Third Quarter 2020 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode. E ...

Verona Pharma plc (NASDAQ:VRNA) Q2 2020 Earnings Conference Call August 14, 2020 9:00 AM ET Company Participants David Zaccardelli - CEO Mark Hahn - CFO Kathy Rickard - CMO Chris Martin - VP, Commercial Conference Call Participants Lucy Codrington - Jefferies Tom Shrader - BTIG Liana Moussatos - Wedbush Securities Joon Lee - Truist Securities Edward Thomason - from N+1 Singer Sharon Ofer - Sphera Fund Management Ltd. Operator Welcome to the Verona Pharma Second Quarter 2020 Financial Results and Operating H ...

Verona Pharma plc (NASDAQ:VRNA) Q1 2020 Earnings Conference Call April 30, 2020 9:00 AM ET Company Participants David Zaccardelli - Chief Executive Officer Mark Hahn - Chief Financial Officer Kathy Rickard - Chief Medical Officer Conference Call Participants Lucy Codrington - Jefferies Tom Shrader - BTIG Liana Moussatos - Wedbush David Zaccardelli Welcome to todayÂ's call. With me today are Mark Hahn, our Chief Financial Officer; and Dr. Kathy Rickard, our Chief Medical Officer. Before I review our progress ...

Verona Pharma plc (NASDAQ:VRNA) Q4 2019 Earnings Conference Call February 27, 2020 9:00 AM ET Company Participants David Zaccardelli - Chief Executive Officer Mark Hahn - Chief Financial Officer Kathy Rickard - Chief Medical Officer Conference Call Participants Julian Harrison - BTIG Liana Moussatos - Wedbush Iris Long - Berenberg Capital Markets Adam Walsh - Stifel Peter Welford - Jefferies Operator Welcome to Verona Pharma Full Year 2019 Financial Results and Operating Highlights Conference Call. All line ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________________________________________ Form 20-F ______________________________________________________________________ (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 ...

Verona Pharma plc (NASDAQ:VRNA) Q3 2019 Results Earnings Conference Call November 5, 2019 8:00 AM ET Company Participants Kimberly Minarovic - Managing Director, Argot Partners Jan-Anders Karlsson - Chief Executive Officer Piers Morgan - Chief Financial Officer Conference Call Participants Lucy Codrington - Jefferies Edwin Zhang - Stifel Liana Moussatos - Wedbush Securities Julian Harrison - BTIG Iris Long - Berenberg Capital Markets Operator Hello ladies and gentlemen, and welcome to the Verona Pharma Thir ...

Verona Pharma plc (NASDAQ:VRNA) Q2 2019 Results Earnings Conference Call August 6, 2019 8:00 AM ET Company Participants Stephanie Carrington - Investor Relations, Managing Director at ICR, Inc. Jan-Anders Karlsson - Chief Executive Officer Piers Morgan - Chief Financial Officer Conference Call Participants Lucy Codrington - Jefferies Liana Moussatos - Wedbush Securities Julian Harrison - BTIG Fang-Ke Huang - SunTrust Robinson Humphrey Neil Carnahan - Stifel Patrick Trucchio - Berenberg Capital Jens Lindqvis ...

Breathtaking science Developing respiratory drugs for better quality of life Jefferies Global Healthcare Conference June 2019 Nasdaq: VRNA AIM: VRP www.veronapharma.com Forward looking statements This presentation contains "forward-looking" statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiaries, the "Company"). All statements other than statements of historical fact contained in this pres ...

RPL554 (dual PDE3/4 enzyme inhibitor): Baseline airway reversibility impacts immediate bronchodilation, in contrast to progressive symptom improvement Dave Singh1, Brian T. Maurer,2 Fernando Martinez,3 Thomas Bengtsson4 1. Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; 2. Verona Pharma, plc, New York, USA; 3. Weill Cornell Medical College, New York, USA; 4. StatMind AB, Lund, Sweden Introduction Figure 1: Peak FEV1 0–3 h ensifentrine–placebo ...